
The development of zzso cardiovascular complications is a common and serious problem for the long-term survivors of organ zzso zzso A plus zzso zzso regimens in these patients are associated with the development of hypertension, zzso zzso and diabetes zzso Whether the new zzso agent zzso zzso zzso any advantage in terms of these cardiovascular risk factors has been less well zzso We compared serial changes in blood pressure, zzso body weight, and zzso levels during the first 12 months after liver transplantation in patients using either zzso A zzso zzso zzso or zzso zzso zzso zzso zzso By 12 months, the prevalence of hypertension, zzso and obesity was increased in the zzso A group compared to zzso zzso versus zzso zzso versus zzso and zzso versus zzso respectively (all p zzso zzso and total cholesterol levels were 196 zzso 23 versus 125 zzso 13 zzso and 225 zzso 9 versus 159 zzso 7 zzso for the zzso A versus zzso groups, respectively zzso zzso zzso zzso steroid dose was not related to the observed zzso changes in either group, although the increase in zzso was positively correlated to weight gain and zzso use in the zzso A zzso The zzso of diabetes zzso was not increased from baseline in either zzso These results indicate that zzso compared to zzso A, is associated with a less adverse cardiovascular risk profile in the first year after liver zzso Whether these differences persist and become clinically relevant to a liver transplant recipient population that is increasingly older and has more zzso cardiovascular disease remains to be zzso 

